Redwood Invest Report
  • Business
  • Politics
  • Stocks
  • Investing
  • Business
  • Politics
  • Stocks
  • Investing

Redwood Invest Report

Politics

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by admin October 3, 2025
October 3, 2025
Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

previous post
Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin
next post
Reagan-appointed judge, once rebuked by Supreme Court, continues to lambaste Trump

Related Posts

‘Full-blown battle’ brewing in Dem party as Mamdani-style...

November 26, 2025

Trump announces escalating tariffs on Denmark and other...

January 18, 2026

Bernie Sanders spent over $550K in 2025 campaign...

February 5, 2026

Mike Tyson in the ‘fight of my life’...

February 12, 2026

Senate GOP hurtles toward nuclear option after deal...

September 12, 2025

Comey indictment sparks fierce political reactions nationwide

September 26, 2025

Iran to suspend work with UN nuclear watchdog,...

July 3, 2025

‘Fiction’: House Republican campaign chair dismisses Democrats’ expanding...

February 14, 2026

Social Security is 90 years old. We are...

August 15, 2025

White House responds to reports of Trump preparing...

November 1, 2025

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • CHARBONE presentera a la conference Hydrogen East et annonce le developpement d’un hub d’approvisionnement dans le marche de l’Atlantique via sa filiale

    • Tartisan Nickel Corp. Intersects 24.6 Metres of 0.71% Ni, 0.56% Cu Including 6.1 Metres of 1.17% Ni, 1.45% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

    • LaFleur Minerals Inc.Taking Key Steps to Advance Position in Prolific Gold Belt

    • NevGold Mobilizes Drill To Test Historical Leach Pads To Advance The Near-Term Antimony Production Scenario at Limo Butte

    • Cartier Cuts 7.1 g/t Au over 8.0 m at Portal ; New Shallow High-Grade Gold Zone Discovered

    • 171 million travelers face airport delays as Democrats’ DHS shutdown hits TSA staffing, Scalise warns

    Categories

    • Business (214)
    • Investing (1,909)
    • Politics (2,292)
    • Stocks (119)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 redwoodinvestreport.com | All Rights Reserved